ZBIO ZENAS BIOPHARMA INC revenue, earnings and financials
For the quarter ended June 30, 2026, ZENAS BIOPHARMA INC reported revenue of $1.00M, net income of −$111M and diluted EPS of −$1.77; for the fiscal year ended December 2025 revenue was $10.0M, up 100.0% on the year before.
ZBIO annual revenue and earnings
- Fiscal year ended Dec 2025: revenue $10.0M, gross profit n/a, operating income −$383M, net income −$378M (margin -3777.4%), EPS −$8.44
- Fiscal year ended Dec 2024: revenue $5.00M, gross profit n/a, operating income −$164M, net income −$157M (margin -3139.8%), EPS −$11.89
- Fiscal year ended Dec 2023: revenue $50.0M, gross profit n/a, operating income −$37.1M, net income −$37.1M (margin -74.2%), EPS −$24.25
ZBIO quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue $1.00M, net income −$111M, EPS −$1.77
- Quarter ended Mar 31, 2026: revenue n/a, net income −$81.0M, EPS −$1.46
- Quarter ended Dec 31, 2025 (from the annual report): revenue $0, net income −$240M, EPS −$5.17
- Quarter ended Sep 30, 2025: revenue $0, net income −$51.5M, EPS −$1.22
- Quarter ended Jun 30, 2025: revenue $0, net income −$52.2M, EPS −$1.25
- Quarter ended Mar 31, 2025: revenue $10.0M, net income −$33.6M, EPS −$0.80
- Quarter ended Dec 31, 2024 (from the annual report): revenue n/a, net income −$52.6M, EPS $35.25
- Quarter ended Sep 30, 2024: revenue $0 (down 100.0% year over year), net income −$38.6M, EPS −$5.02
- Quarter ended Jun 30, 2024: revenue $0, net income −$38.0M, EPS −$24.23
- Quarter ended Mar 31, 2024: revenue n/a, net income −$27.8M, EPS −$17.89
- Quarter ended Dec 31, 2023 (from the annual report): revenue n/a, net income −$24.6M, EPS n/a
- Quarter ended Sep 30, 2023: revenue $50.0M, net income $35.6M, EPS $1.96
- Quarter ended Jun 30, 2023: revenue n/a, net income −$29.0M, EPS n/a
- Quarter ended Mar 31, 2023: revenue n/a, net income −$19.1M, EPS n/a
ZBIO cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$172M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$120M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$30.5M, share buybacks n/a
ZBIO balance sheet
- Jun 30, 2026: cash $197M, total assets $702M, total liabilities $455M, shareholders' equity $247M
- Mar 31, 2026: cash $500M, total assets $748M, total liabilities $412M, shareholders' equity $336M
- Dec 31, 2025: cash $111M, total assets $384M, total liabilities $141M, shareholders' equity $242M, long-term debt $78.6M
- Sep 30, 2025: cash $116M, total assets $322M, total liabilities $126M, shareholders' equity $196M, long-term debt $73.0M
- Jun 30, 2025: cash $44.0M, total assets $293M, total liabilities $53.5M, shareholders' equity $240M
- Mar 31, 2025: cash $197M, total assets $334M, total liabilities $49.4M, shareholders' equity $284M
- Dec 31, 2024: cash $320M, total assets $370M, total liabilities $57.5M, shareholders' equity $312M
- Sep 30, 2024: cash $360M, total assets $403M, total liabilities $44.0M, shareholders' equity $359M
What is ZBIO's revenue?
ZENAS BIOPHARMA INC reported $10.0M of revenue for the fiscal year ended December 2025.
Is ZBIO profitable?
No. ZENAS BIOPHARMA INC lost $484M over the last four quarters.
What is ZBIO's EPS?
Diluted earnings per share over the last four quarters were −$9.62; −$1.77 in the latest quarter.